Search

Displaying results 4691 - 4700 of 9322 in total
  1. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    efficacious than [vedolizumab] and without the CNS effects of [natalizumab]. … [A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal

  2. Drug

    Melitracen

    go.drugbank.com/drugs/DB13384
    Investigational

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. … The Company determined that the program was not meeting their expected primary and exploratory objectives.

  4. Drug

    Cortisone

    go.drugbank.com/drugs/DB14681
    Investigational

    It is converted in the liver to the active metabolite hydrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)

    Synonyms: Kendall's compound E
  5. Drug

    Inosinic Acid

    go.drugbank.com/drugs/DB04566
    Investigational

    A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.

  6. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    It is the morpholinoethyl ester of niflumic acid [L1496]. In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with bronchitis showed improvement [A7889].

  7. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current therapies do not cross the blood-brain barrier … RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  8. Drug

    N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide

    go.drugbank.com/drugs/DB06945
    Experimental

    This compound belongs to the diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. … This substance is known to target a disintegrin and metalloproteinase with thrombospondin motifs 5.

  9. Drug

    Lomedeucitinib

    go.drugbank.com/drugs/DB21649
    Investigational

    The usage of the INN stem '-citinib' in the name indicates that Lomedeucitinib is a Janus kinase inhibitor. … Lomedeucitinib is under investigation in clinical trial NCT05730725 (A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis).

  10. Drug

    Satavaptan

    go.drugbank.com/drugs/DB14923
    Investigational

    Satavaptan is under investigation in clinical trial NCT00359437 (Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver).